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(57) ABSTRACT 
Primitive or progenitor hematologic cancer cells have been 
implicated in the early stages and development of leukemia 
and malignant lymphoproliferative disorders, including acute 
myelogenous leukemia (AML), chronic myelogenous leuke 
mia (CML) and chronic lymphoid leukemia (CLL). Interleu 
kin-3 receptor alpha chain (IL-3Ra or CD123) is strongly 
expressed on progenitor hematologic cancer cells, but is vir 
tually undetectable on normal bone marrow cells. The present 
invention provides methods of impairing progenitor hemato 
logic cancer (e.g., leukemia and lymphomic) cells by selec 
tively targeting cells expressing CD123. These methods are 
useful in the detection and treatment of leukemias and malig 
nant lymphoproliferative disorders. Also provided are com 
pounds useful for selectively binding to CD123 and impairing 
progenitor hematologic cancer cells. These compounds may 
include cytotoxic moieties such as, for example, radioiso 
topes or chemotherapeutics. 
10 Claims, 8 Drawing Sheets 
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METHODS TO IMPAIR HEMATOLOGIC 
CANCER PROGENITOR CELLS AND 
COMPOUNDS RELATED THERETO 
CONTINUING DATA 
The present application is a continuation of US. applica 
tion Ser. No. 10/830,089, ?led Apr. 23, 2004, now US. Pat. 
No. 7,651,678, which is a continuation of US. application 
Ser. No. 09/799,100, ?led Mar. 6, 2001, now US. Pat. No. 
6,733,743, which claims the bene?t of priority to US. Pro 
visional Patent Application Nos. 60/187,123, ?led Mar. 6, 
2000, and 60/227,295, ?ledAug. 24, 2000, the disclosures of 
each of which are incorporated by reference herein in their 
entirety. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention is related to methods of impairing 
progenitor hematologic cancer cells or treating hematologic 
cancer by targeting a cell surface marker speci?c for progeni 
tor hematologic cancer cells. The present invention is also 
related to a method for diagnosing hematologic cancer. 
2. Background of the Invention 
Stem cells are commonly found in a variety of mammalian 
tissue systems. While the criteria by which such cells are 
de?ned vary depending upon the speci?c context, two prop 
erties are generally regarded as central features of stem cell 
populations: (1) stem cells must exhibit some capacity for 
self-replication or self-renewal, and (2) stem cells must be 
capable of differentiating into appropriate lineages (Potten C 
S: Stem Cells. London, Academic Press, 1997). Cells of this 
nature have been described for a number of tissues including 
hematopoietic, embryonic, neural, muscle and hepatic sys 
tems (Lemischka I R. Clonal, in vivo behavior of the totipo 
tent hematopoietic stem cell. Semin Immunol 1991, 3: 349 
55; Morrison S J, et al., The biology of hematopoietic stem 
cells.Annu. Rev. Cell Dev. Biol. 1995, 11: 35-71; Robertson 
E 1., Using embryonic stem cells to introduce mutations into 
the mouse germ line. Biol Reprod 1991, 44: 238-45; Gage F 
H., Mammalian neural stem cells. Science 2000, 287: 1433-8; 
and, Alison M, et al., Hepatic stem cells. J Hepatal 1998, 29: 
676-82). Thus, it is perhaps not surprising that similar cells 
have recently been documented in the context of malignant 
populations (Bonnet D, et al., Human acute myeloid leukemia 
is organized as a hierarchy that originates from a primitive 
hematopoietic cell. Nat. Med. 1997, 3: 730-737; Blair A, et 
al., Most acute myeloid leukemia progenitor cells with long 
term proliferative ability in vitro and in vivo have the pheno 
type CD34(+)/CD71(—)/HLA-DR—. Blood 1998, 92: 4325 
35; Cobaleda C, et al., A primitive hematopoietic cell is the 
target for the leukemic transformation in human Philadel 
phia-positive acute lymphoblastic leukemia. Blood 2000, 95: 
1007-13). Indeed, a stem cell is in some respects the ideal 
target for malignant transformation in that relatively little 
biological change is required. Since stem cells already pos 
sess the genetic programming necessary to be highly prolif 
erative and developmentally plastic, one can imagine that 
relatively subtle perturbations might be suf?cient to induce 
disease. 
One example of neoplasia arising from malignant stem 
cells has recently been documented in the hematopoietic sys 
tem in the case of acute myelogenous leukemia (AML). This 
disease is characterized by premature arrest of myeloid devel 
opment and the subsequent accumulation of large numbers of 
non-functional leukemic blasts. While leukemic blast cells 
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are often of clonal origin and display relatively homogeneous 
features, it has been demonstrated that such populations are 
organized in a hierarchical fashion, analogous to normal 
hematopoietic progenitors. Thus, there is a phenotypically 
de?ned leukemic stem cell population that is suf?cient to 
propagate leukemic blasts both in vitro and in vivo in xeno 
geneic mouse models of human AML (Bonnet D, et al., 
Human acute myeloid leukemia is organized as a hierarchy 
that originates from a primitive hematopoietic cell. Nat. Med. 
1997, 3: 730-737; Blair A, et al., Most acute myeloid leuke 
mia progenitor cells with long-term proliferative ability in 
vitro and in vivo have the phenotype CD34(+)/CD71(—)/ 
HLA-DR—. Blood 1998, 92: 4325-35, Cobaleda C, et al., A 
primitive hematopoietic cell is the target for the leukemic 
transformation in human Philadelphia-positive acute lym 
phoblastic leukemia. Blood 2000, 95: 1007-13; BlairA, et al. 
Lack of expression of Thy-1 (CD90) on acute myeloid leu 
kemia cells with long-term proliferative ability in vitro and in 
vivo. Blood 1997, 89: 3104-12). The concept ofa leukemic 
stem cell (LSC) becomes critically important in considering 
the etiology of human disease. Clearly, in order to achieve 
durable remission, it will be necessary to speci?cally ablate 
the primitive or progenitor LSC population. However, previ 
ous studies (Terpstra W, et al., Fluorouracil selectively spares 
acute myeloid leukemia cells with long-term growth abilities 
in immunode?cient mice and in culture. Blood 1996, 88: 
1944-50), as well as data from our group, suggest that LSC’s 
are biologically distinct from more mature leukemic blasts 
and may not be responsive to conventional chemotherapeutic 
regimens. This observation is consistent with the clinical 
pro?le frequently seen for AML, wherein a majority of 
patients can achieve apparent complete remission, but in most 
cases will relapse (Schiller G 1., Treatment of resistant dis 
ease. Leukemia 1998, 12 Suppl 1: S20-4; Paietta E., Classical 
multidrug resistance in acute myeloid leukemia. Med Oncol 
1997, 14: 53-60). If LSC’s are more refractile to chemo 
therapy than blasts, it is attractive to propose that surviving 
stem cells are a major contributing factor to leukemic relapse. 
Thus, strategies that speci?cally target progenitor leukemia 
cells may provide more effective treatment for leukemia 
patients. In 1997, Bonnet and Dick described the phenotype 
for LSC’s as CD34+/CD38— (Bonnet D, et al., Human acute 
myeloid leukemia is organized as a hierarchy that originates 
from a primitive hematopoietic cell. Nat. Med. 1997, 3: 730 
737). We report that the IL-3 receptor alpha chain (CD123) is 
highly expressed on leukemic but not normal CD34+/CD38— 
hematopoietic cells. In view of this state of the art, there is a 
need in the art to provide a diagnostic method for detecting 
leukemia at an early stage, as well as more effective methods 
of treating this disease. 
SUMMARY OF THE INVENTION 
The present invention relates to a method of using com 
pounds that bind to the human CD123 molecule (CD123 
ectopeptide), in the diagnosis and treatment of hematologic 
cancers (e.g., leukemias and malignant lymphoproliferative 
disorders). The CD123 speci?c compounds and mimetics 
have particular utility as pharmaceuticals and reagents for the 
therapy of hematologic cancer or malignant disease states and 
for the diagnosis of hematologic cancer disease states. In one 
embodiment, the present invention provides a method of 
impairing a hematologic cancer progenitor cell comprising 
contacting the cell with a compound that selectively binds to 
CD 1 23 in an amount effective to impair the progenitor hema 
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tologic cancer cell. This contacting step may occur in various 
environments, including in vitro and in vivo in the body of an 
animal, including a human. 
Throughout this application, reference will be made spe 
ci?cally to leukemia in describing certain embodiments of the 
present invention. However, it is understood that the present 
invention is not limited to diagnosis and treatment of leuke 
mia or malignant lymphoproliferative disorders alone, but to 
any disease in which the cancerous cells selectively express 
CD123, which includes the genus of hematologic cancer. 
In one embodiment, the present invention is directed to a 
method of detecting the presence of CD123 on, for example, 
a leukemia progenitor cell. Thus, the invention is also directed 
to a method of diagnosing leukemia. It is understood that by 
using a labeled ligand to bind to CD123, it is possible to detect 
the presence of leukemia progenitor cells. Thus, it is also 
possible to diagnose the likelihood of the onset of leukemia in 
patients possessing such leukemic progenitor cells express 
ing CD123. The CD123 binding ligand may be an antibody to 
CD123, or it may be any of a variety of molecules that spe 
ci?cally bind to CD123. Furthermore, the label can be chosen 
from any of a variety of molecules, including, but not limited 
to, enzymatic compounds, or non-enzymatic compounds that 
serve as a reporter of the presence of the ligand which has 
bound to the CD123 molecule. Examples of such labels 
include those that are, for example, radioactive, ?uorescent, 
chemiluminescent or absorbant-based, or a combination of 
the foregoing. In one embodiment, an assay is provided for 
detecting the presence of progenitor leukemia cells in a 
sample by detecting the presence of CD123 in the sample, 
which may be accomplished by introducing a compound that 
selectively binds to CD123 and determining whether the 
compound binds to a component of the sample. 
In another series of embodiments, the present invention 
also provides compounds or molecules which mimic (mimet 
ics) the three-dimensional structure of part or all of the com 
pounds such as peptides, antibodies, carbohydrates, lipids or 
nucleic acids that bind to CD123, and in the case of antibod 
ies, of the binding pockets of the antibodies, or of the comple 
mentarity determining regions (CDR’s). 
The present invention also provides pharmaceutical prepa 
rations comprising a pharmaceutically acceptable carrier; and 
any one or more of the CD123 speci?c compounds and 
mimetics described above. 
In another set of embodiments, the present invention pro 
vides a method for the treatment of leukemia, comprising 
administering to a human subject or other animal in need of 
such treatment a therapeutically effective amount of the com 
pounds or their mimetic pharmaceutical compositions 
described above. 
In still another set of embodiments, the present invention 
provides a method of selectively purging leukemic stem cells 
from bone marrow. These stems cells may give rise to leuke 
mia progenitor cells, or they may be the progenitor cells, 
which may be impaired by the method of the invention using 
various compounds or their mimetics and cytotoxic agents 
that may be contacted to either a bone marrow sample or 
injected into a bone marrow of an individual, thereby destroy 
ing at least some of the leukemic stem cells in the bone 
marrow. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention will become more fully understood 
from the detailed description given herein below, and the 
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4 
accompanying drawings which are given by way of illustra 
tion only, and thus are not limiting of the present invention, 
and wherein: 
FIGS. 1A and 1B show CD123 expression on normal and 
leukemic hematopoietic cells. Representative examples of 
CD123 labeling in cells derived from normal bone marrow 
(panel A) or primary AML peripheral blood (panel B) are 
provided. The inset polygon in panel A (left dot plot) indicates 
the percentage of total bone marrow that is positive for 
CD123 expression (7%). The smaller rectangular gate indi 
cates the proportion of total marrow strongly positive for 
CD123 (1%). The center dot plot in panel A shows bone 
marrow that was enriched for CD34+ cells by selection on an 
immunoaf?nity column (see methods). The gates indicate the 
total CD34+ population and the CD34+/CD38— population. 
The histograms indicate the CD123 labeling for the two gated 
populations. Panel B shows the same analysis for the primary 
AML specimen. M1 markers in the histograms indicate 
expression levels that are higher than 99% of isotype control 
samples. For each specimen, 50,000-100,000 events were 
analyzed. 
FIG. 2 shows CD expression on ?ve primitive AML popu 
lations. Five primary AML specimens were labeled with 
CD34, CD38, and CD123 and analyzed by ?ow cytometry. 
The ?gure shows CD123 labeling for the CD34+/CD38— 
gated populations from each sample. The dark sections indi 
cate CD123 staining and the light sections indicate parallel 
labeling with an isotype control antibody. M1 markers in the 
histograms indicate expression levels that are higher than 
99% of isotype control samples. For each specimen, 50,000 
100,000 events were analyzed. 
FIGS. 3A and 3B show engraftment of CD123+ AML cells 
in NOD/SCID mice. Sorted CD34+/CD123+ primary AML 
cells were transplanted into an irradiated NOD/SCID mouse. 
Six weeks post-transplant, bone marrow cells were isolated 
and analyzed for the presence of human (CD45+) leukemic 
cells. Panel A shows the CD34 vs. CD45 pro?le of an 
engrafted specimen using antibodies that are speci?c to 
human cells. Panel B shows the CD34 vs. CD123 pro?le of 
the CD45+ gated human cell population. For each sample, 
50,000 events were analyzed. 
FIG. 4 shows CD123 and CD131 immunoblot analysis of 
primary AML specimens. Five primary AML samples were 
derived from peripheral blood and sorted to isolate the 
CD34+ population, thus insuring a virtually pure leukemic 
sample. In addition, the leukemic cell line TF-1 (TF-1) and 
normal marrow CD34+ cells (normal CD34+) were included 
as controls. Lysates were made from each population, subject 
to denaturing PAGE and analyzed by immunoblot with an 
anti-CD123 antibody (top panel) or an anti-CD131 antibody 
(bottom panel). The arrowhead at the left of each panel indi 
cates the position of the IL-3RO. (CD123) and IL-3R[3 
(CD 1 3 1) chains, respectively. 
FIGS. 5A, 5B and 5C show phosphorylation of signal 
transduction components in response to IL-3. Three primary 
AML samples (Lanes 1-3) were derived from peripheral 
blood and sorted to isolate the CD34+ population. Samples 
were treated with (+) or without (—) 20 ng/ml IL-3 for 15 
minutes, then lysed and subj ected to PAGE. Each gel was then 
electro-blotted and membranes were probed with antibodies 
speci?c to either total or phosphorylated protein for Akt (A), 
Stat5 (B), and Mek-1 (C). The lane labeled C on each blot is an 
antibody control and is derived from NIH 3T3 cells treated 
+/—50 ng/ml PDGF (A and C), or TF-1 cells treated +/—25 
ng/ml GM-SCF (B). 
FIGS. 6A, 6B and 6C show CD123 expression in primary 
ALL. Flow cytometric analysis of CD123 expression on three 
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independent primary ALL (acute lymphoid leukemia) speci 
mens. CD123 labeling is shown by the ?lled (dark) plots and 
controls are shown by open plots. 
FIGS. 7A, 7B and 7C show CD123 expression in primary 
CML. Flow cytometric analysis of CD123 expression on 
three independent primary CML (chronic myelogenous leu 
kemia) specimens. CD123 labeling is shown by the ?lled 
(dark) plots and controls are shown by open plots. 
DETAILED DESCRIPTION OF THE INVENTION 
De?nitions 
As used herein, the term “antibody” means an immunoglo 
bulin molecule, or a fragment of an immunoglobulin mol 
ecule, having the ability to speci?cally bind to a particular 
antigen. Antibodies are well known to those of ordinary skill 
in the science of immunology. As used herein, the term “anti 
body” means not only intact antibody molecules but also 
fragments of antibody molecules retaining antigen-binding 
ability. Such fragments are also well known in the art and are 
regularly employed both in vitro and in vivo. In particular, as 
used herein, the term “antibody” means not only intact immu 
noglobulin molecules but also the well-known active frag 
ments F(ab')2, Fab, Fv, Fd, VH and VL. 
As used herein, the terms “bind” or “bind(s)” shall mean 
any interaction, whether via direct or indirect means, which 
affects the speci?ed receptor or receptor subunit. 
As used herein, the terms “binds selectively to” shall mean 
that the compound, composition, formulation, etc. does not 
signi?cantly bind IL3R beta chain, but does bind IL3R alpha 
chain. 
As used herein, the terms “CD123”, “IL3R subunit alpha” 
and “IL3RO.” shall be used interchangeably to mean an anti 
genic determinant that is detectable in leukemia precursor 
cells as described herein, but not detectable on normal cells as 
described herein. 
As used herein, the term “compoun shall mean any 
purity of active ingredient, including formulations, composi 
tions, naturally-occurring plants or animals, etc. The com 
pound may include molecules that are naturally occurring, 
such as proteins, nucleic acids, single stranded nucleic acids, 
lipids, carbohydrates, and antibodies. However, synthetic 
versions of these naturally occurring molecules may be made, 
so long as they bind CD123. The compounds may comprise 
more than one component. For example, a compound may be 
a monoclonal antibody attached to a toxin. Or, it may be a 
lipid attached to a label. The compounds may further com 
prise mimetics, and aptamers, but which all retain their speci 
?city to CD123. 
As used herein, the term “impair” shall mean any decrease 
in functionality or activity (including growth or proliferative 
activity). 
As used herein, the term “hematologic cancer” refers to a 
cancer of the blood, and includes leukemia and malignant 
lymphoproliferative disorders, among others. “Leukemia” 
refers to a cancer of the blood, in which too many white blood 
cells that are ineffective in ?ghting infection are made, thus 
crowding out the other parts that make up the blood, such as 
platelets and red blood cells. It is understood that cases of 
leukemia are classi?ed as acute or chronic. Cancer cells in 
acute leukemias are blocked at an immature stage. However, 
they continue to multiply. Consequently, there is a large accu 
mulation of non-functional immature cells and the concomi 
tant loss of functional cells. Chronic leukemias progress more 
slowly, with cancer cells developing to full maturity. Further 
more, the white blood cells may be myelogenous or lym 
a, 
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phoid. Thus, certain forms of leukemia may be, by way of 
example, acute lymphatic (or lymphoblastic) leukemia 
(ALL); acute myelogenic leukemia (AML); chronic lympho 
cytic leukemia (CLL); or chronic myelogenic leukemia 
(CML); and myelodysplastic syndrome. “Malignant lym 
phoproliferative disorders” may refer to a lymphoma, such as 
multiple myeloma, non-Hodgkin’s lymphoma, Burkitt’s 
lymphoma, and follicular lymphoma (small cell and large 
cell), among others. For purposes of this invention, at least 
some of the hematologic cancer cells are characterized by 
cells that express CD123.Also, for the purposes of this appli 
cation, whenever leukemia or malignant lymphoproliferative 
disorders are mentioned, the diagnostic and treatment method 
of the invention applies generally to hematologic cancer. 
As used herein, the term “introducing” shall mean any 
means of delivery, whether in vivo or in vitro, including 
simple contact. 
As used herein, the term “mimetic” means a compound or 
molecule which mimics the three-dimensional structures of a 
site on CD123 to which a compound may bind, or the com 
pound may be a molecule that mimics a molecule that binds to 
CD123. In the case of an anti-CD123 antibody binding site, or 
paratope, or active site, “mimetic” means a compound that 
mimics the three-dimensional structure of any combination 
of the antibody hypervariable loops or complementarity 
determining regions (CDR’ s). 
As used herein, the term “mimic” means the three-dimen 
sional placement of atoms of the mimetic such that similar 
ionic forces, covalent forces, van der Waal’s or other forces, 
and similar charge complementarity, or electrostatic comple 
mentarity, exist between the atoms of the mimetic and the 
atoms of the binding site of the compound such as a peptide or 
an antibody such that the mimetic has a similar binding a?in 
ity for CD123 as the parent compound and/or such that the 
mimetic has a similar effect on the function of CD123 in vitro 
or in vivo. 
In the case of anti-CD123 antibodies, within the antigen 
binding portion of an antibody, as is well-known in the art, 
there are complementarity determining regions (CDRs), 
which directly interact with the epitope of the antigen, and 
framework regions (FRs), which maintain the tertiary struc 
ture of the paratope. In both the heavy chain Fd fragment and 
the light chain of IgG immunoglobulins, there are four frame 
work regions (FRl through FR4) separated respectively by 
three complementarity determining regions (CDR1 through 
CDR3). The CDRs, and in particular the CDR3 regions, and 
more particularly the heavy chain CDR3, are largely respon 
sible for antibody speci?city. 
As used herein, the term “normal” means any non-patho 
genic or non-pathology-related cells or conditions. 
As used herein, the terms “primitive” and “progenitor” 
shall be interchangeable. As used herein, with respect to 
polypeptides and antibodies, the term “substantially pure” 
means that the polypeptides are substantially free of other 
substances with which they may be found in nature or in vivo 
systems to an extent practical and appropriate for their 
intended use. In particular, the polypeptides are suf?ciently 
pure and are suf?ciently free from other biological constitu 
ents of their host cells so as to be useful in, for example, 
generating antibodies, sequencing, or producing pharmaceu 
tical preparations. By techniques well known in the art, sub 
stantially pure polypeptides may be produced in light of the 
nucleic acid and amino acid sequences disclosed herein. 
Because a substantially puri?ed polypeptide of the invention 
may be admixed with a pharmaceutically acceptable carrier 
in a pharmaceutical preparation, the polypeptide may com 
prise only a small percentage by weight of the preparation. 
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The polypeptide is nonetheless substantially pure in that it has 
been substantially separated from the substances with which 
it may be associated in living systems. 
As used herein with respect to compounds or mimetics, the 
term “substantially pure” means that the compounds are sub 
stantially free of other substances with which they may be 
found, in nature, in in vivo systems; or as a result of chemical 
or other synthesis, to an extent practical and appropriate for 
their intended use. In particular, the compounds are suf? 
ciently pure and are suf?ciently free from other biological 
constituents of their hosts cells, or chemical or physical con 
stituents of their synthesis so as to be useful in, producing 
pharmaceutical preparations. By techniques well known in 
the art (US. Pat. No. 5,648,379; Colman, P. G. Protein Sci 
ence 3: 1687-1696, 1994; Malby, et al., Structure 2: 733-746, 
1994; McCoy et al., 1 Molecular Biol. 268: 570-584, 1997), 
substantially pure compounds or mimetics, may be designed. 
Because a substantially puri?ed compound of the invention 
may be admixed with a pharmaceutically acceptable carrier 
in a pharmaceutical preparation, the compound may com 
prise only a small percentage by weight of the preparation. 
The compound is nonetheless substantially pure in that it has 
been substantially separated from the substances with which 
it may be associated in living, chemical or other systems. 
Mimetics That Bind to CD123 
Compounds that target CD123 can be found. Phage display 
libraries can be used to determine the DNA encoding the 
polypeptide that binds to CD123. The principles of this 
approach are disclosed in US. Pat. No. 5,837,500, which is 
incorporated by reference herein in its entirety. Other non 
peptide molecules that may bind to CD123 include nucleic 
acids, and liposomes. Carbohydrates may also be used to 
target CD123. It is possible that the compound may not be a 
naturally occurring biological molecule. Such chemicals may 
be made by combinatorial libraries which are well known in 
the art, with the assay goal being the binding of the chemical 
compound to CD123. Liposomes may ensconce certain tox 
ins or other cell-impairing substances or cell-imaging com 
pounds may be used to target CD123. Numerous variations 
and combinations of compounds as targeting agents are con 
templated by the method of the invention, so long as CD123 
is targeted, with the knowledge that leukemia detection and 
leukemia treatment is kept in mind. 
Mimetics of Anti-CD123 Antibodies 
It is also possible to use the anti-idiotype technology to 
isolate or screen for compounds or mimetics which mimic an 
epitope. Thus, an anti-idiotypic monoclonal antibody which 
is the image of the epitope bound by the ?rst monoclonal 
antibody, since it effectively acts as an antigen, may be used 
to isolate mimetics from a combinatorial chemical, or other 
libraries, of chemical or other compounds, such as peptide 
phage display libraries (Scott and Smith, Science 249: 386 
390, 1990; Scott and Craig, Curr. Opin. Biotechnol. 5: 40-48, 
1992; Bonnycastle et al., J. Mol. Biol. 258: 747-762, 1996). 
Hence, peptides or constrained peptides mimicking proteins 
or other compounds, including those with nucleic acid, lipid, 
carbohydrate or other moieties, may be cloned (Harris et al., 
Proc. Natl. Acad. Sci. (USA) 94: 2454-2459, 1997). 
Purely synthetic molecules, which may not occur in nature 
and are therefore more resistant to catabolism, excretion or 
degradation, may be designed by the three-dimensional 
placement of atoms, such that similar ionic forces, covalent 
forces, van der Waal’s or other forces, and similar charge 
complementarity, or electrostatic complementarity, exist 
between the atoms of the mimetic and the atoms of the anti 
genic binding site or epitope. These mimetics may then be 
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screened for high af?nity binding to CD123 and detect and/or 
impair the CD123 bearing cell in vitro or in vivo, as described 
in more detail below. 
Diagnostic and Pharmaceutical Preparations 
The invention also relates to a method for preparing diag 
nostic or pharmaceutical compositions comprising the 
CD123 binding compound and its mimetics. The pharmaceu 
tical preparation includes a pharmaceutically acceptable car 
rier. Such carriers, as used herein, mean non-toxic materials 
that do not interfere with the effectiveness of the biological 
activity of the active ingredients. The term “physiologically 
acceptable” refers to a non-toxic material that is compatible 
with a biological system such as a cell, cell culture, tissue, or 
organism. The characteristics of the carrier will depend on the 
route of administration. Physiologically and pharmaceuti 
cally acceptable carriers include diluents, ?llers, salts, buff 
ers, stabilizers, solubilizers, and other materials that are well 
known in the art. 
The anti-CD123 antibodies and mimetics may be labeled 
by a variety of means for use in diagnostic and/or pharma 
ceutical applications. There are many different labels and 
methods of labeling known to those of ordinary skill in the art. 
Examples of the types of labels which can be used in the 
present invention include enzymes, radioisotopes, ?uores 
cent compounds, colloidal metals, chemiluminescent com 
pounds, and bioluminescent compounds. Those of ordinary 
skill in the art will know of other suitable labels for binding to 
the CD123 binding compound, such as monoclonal antibod 
ies, or mimetics thereof, or will be able to ascertain such, 
using routine experimentation. Furthermore, the binding of 
these labels to the CD123 speci?c compounds or their mimet 
ics canbe done using standard techniques common to those of 
ordinary skill in the art. 
In the case of antibodies, another labeling technique which 
may result in greater sensitivity consists of coupling the anti 
bodies or mimetics to low molecular weight haptens. These 
haptens can then be speci?cally altered by means of a second 
reaction. For example, it is common to use haptens such as 
biotin, which reacts with avidin, or dinitrophenol, pyridoxal, 
or ?uorescein, which can react with speci?c anti-hapten anti 
bodies. 
Diagnostic and Treatment Kits 
The materials for use in the assay of the invention are 
ideally suited for the preparation of a kit. Such a kit may 
comprise a carrier means being compartmentalized to receive 
in close con?nement one or more container means such as 
vials, tubes, and the like, each of the container means com 
prising one of the separate elements to be used in the method. 
For example, one of the container means may comprise a 
compound that binds to CD123, such as a monoclonal anti 
body, or a mimetic thereof, which is, or can be, detectably 
labeled with a label that is suitable for diagnostic purposes or 
if treatment is desired, a cytotoxic or impairing agent. In the 
case of a diagnostic kit, the kit may also have containers 
containing buffer(s) and/ or a container comprising a reporter 
means, such as a biotin-binding protein, such as avidin or 
streptavidin, bound to a reporter molecule, such as an enzy 
matic or ?uorescent label. In addition to the chemical mate 
rial, of course a means of instructions for using the kit is 
included, preferably for either diagnosing leukemia, or treat 
ing leukemia. The instruction means may be written on the 
vial, tube and the like, or written on a separate paper, or on the 
outside or inside of the container. The instructions may also 
be in the form of a multi-media format, such as CD, computer 
disk, video and so on. 
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Preparation of lmmunotoxins 
While the preparation of immunotoxins is, in general, well 
known in the art (see, e.g., US. Pat. No. 4,340,535, and EP 
44167, both incorporated herein by reference), the inventors 
are aware that certain advantages may be achieved through 
the application of certain preferred technology, both in the 
preparation of the immunotoxins and in their puri?cation for 
subsequent clinical administration. For example, while lgG 
based immunotoxins will typically exhibit better binding 
capability and slower blood clearance than their Fab' coun 
terparts, Fab' fragment-based immunotoxins will generally 
exhibit better tissue penetrating capability as compared to 
lgG based immunotoxins. 
Additionally, while numerous types of disul?de-bond con 
taining linkers are known which can successfully be 
employed to conjugate the toxin moiety with the binding 
agent, certain linkers will generally be preferred over other 
linkers, based on differing pharmacologic characteristics and 
capabilities. For example, linkers that contain a disul?de 
bond that is sterically “hindered” are to be preferred, due to 
their greater stability in vivo, thus preventing release of the 
toxin moiety prior to binding at the site of action. 
Cross-linking reagents are used to form molecular bridges 
that tie together functional groups of two different proteins 
(e.g., a toxin and a binding agent). To link two different 
proteins in a step-wise manner, hetero bifunctional cross 
linkers can be used which eliminate the unwanted homopoly 
mer formation. An exemplary hetero bifunctional cross 
linker contains two reactive groups: one reacting with 
primary amine group (e.g., N-hydroxy succinimide) and the 
other reacting with a thiol group (e. g., pyridyl disul?de, male 
imides, halogens, etc.). Through the primary amine reactive 
group, the cross-linker may react with the lysine residue(s) of 
one protein (e.g., the selected antibody or fragment) and 
through the thiol reactive group, the cross-linker, already tied 
up to the ?rst protein, reacts with the cysteine residue (free 
sulfhydryl group) of the other protein (e. g., dgA). 
The spacer arm between these two reactive, groups of any 
cross-linkers may have various lengths and chemical compo 
sitions. A longer spacer arm allows a better ?exibility of the 
conjugate components while some particular components in 
the bridge (e.g., benzene group) may lend extra stability to the 
reactive group or an increased resistance of the chemical link 
to the action of various aspects (e.g., disul?de bond resistant 
to reducing agents). 
The most preferred cross-linking reagent is SMPT, which 
is a bifunctional cross-linker containing a disul?de bond that 
is “sterically hindered” by an adjacent benzene ring and 
methyl groups. It is believed that stearic hindrance of the 
disul?de bond serves a function of protecting the bond from 
attack by thiolate anions such as glutathione which can be 
present in tissues and blood, and thereby help in preventing 
decoupling of the conjugate prior to its delivery to the site of 
action by the binding agent. The SMPT cross-linking reagent, 
as with many other known cross-linking reagents, lends the 
ability to cross-link functional groups such as the SH of 
cysteine or primary amines (e.g., the epsilon amino group of 
lysine). Another possible type of cross-linker includes the 
hetero-bifunctional photoreactive phenylazides containing a 
cleavable disul?de bond such as sulfosuccinimidyl-2-(p 
azido salicylamido)ethyl-1,3'-dithiopropionate. The N-hy 
droxy-succinimidyl group reacts with primary amino groups 
and the phenylazide (upon photolysis) reacts non-selectively 
with any amino acid residue. 
Although the “hindered” cross-linkers will generally be 
preferred in the practice of the invention, non-hindered link 
ers can be employed and advantages in accordance herewith 
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nevertheless realized. Other useful cross-linkers, not consid 
ered to contain or generate a protected disul?de, include 
SATA, SPDP and 2-iminothiolane. The use of such cross 
linkers is well understood in the art. 
Once conjugated, it will be important to purify the conju 
gate so as to remove contaminants such as unconjugated A 
chain or binding agent. It is important to remove unconju 
gatedA chain because of the possibility of increased toxicity. 
Moreover, it is important to remove unconjugated binding 
agent to avoid the possibility of competition for the antigen 
between conjugated and unconjugated species. In any event, 
a number of puri?cation techniques are disclosed in the 
Examples below which have been found to provide conju 
gates to a suf?cient degree of purity to render them clinically 
useful. In general, the most preferred technique will incorpo 
rate the use of Blue-Sepharose with a gel ?ltration or gel 
permeation step. Blue-Sepharose is a column matrix com 
posed of Cibacron Blue. 3GA and agarose, which has been 
found to be useful in the puri?cation of immunoconjugates. 
The use of Blue-Sepharose combines the properties of ion 
exchange withA chain binding to provide good separation of 
conjugated from unconjugated binding. 
The Blue-Sepharose allows the elimination of the free (non 
conjugated) binding agent (e.g., the antibody or fragment) 
from the conjugate preparation. To eliminate the free (uncon 
jugated) toxin (e.g., dgA) a molecular exclusion chromatog 
raphy step is preferred using either conventional gel ?ltration 
procedure or high performance liquid chromatography. 
After a suf?ciently puri?ed conjugate has been prepared, 
one will desire to prepare it into a pharmaceutical composi 
tion that may be administered parenterally. This is done by 
using for the last puri?cation step a medium with a suitable 
pharmaceutical composition. 
Suitable pharmaceutical compositions in accordance with 
the invention will generally comprise from about 10 to about 
100 mg of the desired conjugate admixed with an acceptable 
pharmaceutical diluent or excipient, such as a sterile aqueous 
solution, to give a ?nal concentration of about 0.25 to about 
2.5 mg/ml with respect to the conjugate. Such formulations 
will typically include buffers such as phosphate buffered 
saline (PBS), or additional additives such as pharmaceutical 
excipients, stabilizing agents such as BSA or HSA, or salts 
such as sodium chloride. For parenteral administration it is 
generally desirable to further render such compositions phar 
maceutically acceptable by insuring their sterility, non-im 
munogenicity and non-pyrogenicity. Such techniques are 
generally well known in the art as exempli?ed by Reming 
ton’s Pharmaceutical Sciences, 16th Ed. Mack Publishing 
Company, 1980, incorporated herein by reference. It should 
be appreciated that endotoxin contamination should be kept 
minimally at a safe level, for example, less than 0.5 ng/mg 
protein. Moreover, for human administration, preparations 
should meet sterility, pyrogenicity, general safety and purity 
standards as required by FDA Of?ce of Biological Standards. 
A preferred parenteral formulation of the immunotoxins in 
accordance with the present invention is 0.25 to 2.5 mg con 
jugate/ml in 0.15M NaCl aqueous solution at pH 7.5 to 9.0. 
The preparations may be stored frozen at —100 C. to —700 C. 
for at least 1 year. 
It is contemplated that most therapeutic applications of the 
present invention will involve the targeting of a toxin moiety 
(cytotoxic agent) to the CD123 leukemia marker. This is due 
to the much greater ability of most toxins to deliver a cell 
killing effect as compared to other potential agents. 
However, there may be circumstances such as when the 
target antigen does not internalize by a route consistent with 
ef?cient intoxication by immunotoxins, where one will desire 
US 8,852,551 B2 
11 
to target chemotherapeutic agents such as cytokines, antime 
tabolites, alkylating agents, hormones, and the like. The 
advantages of these agents over their non-antibody conju 
gated counterparts is the added selectivity afforded by the 
antibody. One might mention by way of example agents such 
as steroids, cytosine arabinoside, methotrexate, aminopterin, 
anthracyclines, mitomycin C, vinca alkaloids, demecolcine, 
etopside, mithramycin, and the like. This list is, of course, 
merely exemplary in that the technology for attaching phar 
maceutical agents to antibodies for speci?c delivery to tissues 
is well established. 
One preferred cytotoxic moiety for use in the present 
invention is a radioisotope, which can be coupled to or con 
jugated with, for example, an anti-CD 123 antibody. Preferred 
radioisotopes include (x-emitters such as, for example, 
leAstatine, 212Bismuth and 213Bismuth, as well as [3-emit 
ters such as, for example, 13 lIodine, 90Yttrium, 177Lutetium, 
153 Samarium and 109Palladium. Particularly preferred radio 
isotopes are 211Astatine and 131Iodine. 
It is proposed that particular bene?ts may also be achieved 
through the application of the invention to cell imaging. 
Imaging of leukemia cells is believed to provide a major 
advantage when compared to available imaging techniques, 
in that the cells are readily accessible. 
Moreover, the technology for attaching paramagnetic, 
radioactive and even ?uorogenic ions to antibodies is well 
established. Many of these methods involve the use of a metal 
chelate complex employing, for example, an organic chelat 
ing agent such a DTPA attached to the antibody (see, e.g., 
US. Pat. No. 4,472,509). In the context of the present inven 
tion the selected ion is thus targeted to the cancerous area by 
the antibody, allowing imaging to proceed by means of the 
attached ion. 
In a preferred embodiment, in the method of the invention, 
the antibodies may also be fused to a protein effector mol 
ecule by recombinant means such as through the use of 
recombinant DNA techniques to produce a nucleic acid 
which encodes both the antibody and the effector molecule 
and expressing the DNA sequence in a host cell such as E. 
coli. The DNA encoding the chimeric protein may be cloned 
in cDNA or in genomic form by any cloning procedure known 
to those skilled in the art. See for example Sambrook et al., 
Molecular Cloning: A Laboratory Manual, Cold Spring Har 
bor Laboratory, (1989), which is herein incorporated by ref 
erence. 
Fusion or conjugation of antibodies to various labels pro 
duces a highly speci?c detectable marker that may be used to 
detect the presence or absence of cells or tissues bearing the 
particular molecule to which the antibody is detected. Alter 
natively, the antibodies may be chemically conjugated or 
fused to an effector molecule that is another speci?c binding 
moiety, e.g. a ligand such as those described above. In this 
form the composition will act as a highly speci?c bifunctional 
linker. This linker may act to bind and enhance the interaction 
between cells or cellular components to which the fusion 
protein binds. Thus, for example, where the fusion protein is 
a growth factor joined to an antibody or antibody fragment 
(e.g. an Fv fragment of an antibody), the antibody may spe 
ci?cally bind antigen positive cancer cells while the growth 
factor binds receptors on the surface of immune cells. The 
fusion protein may thus act to enhance and direct an immune 
response toward target cancer cells. 
In Vitro Detection and Diagnostics 
The method of using the compounds that bind to CD123 
and their mimetics are suited for in vitro use, for example, in 
immunoassays in which they canbe utilized in liquid phase or 
bound to a solid phase carrier. In addition, the monoclonal 
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antibodies in these immunoassays can be detectably labeled 
in various ways. Examples of types of immunoassays which 
can utilize the monoclonal antibodies and their mimetics are 
competitive and non-competitive immunoassays in either a 
direct or indirect format. Examples of such immunoassays are 
the radioimmunoassay (RIA) and the sandwich (immuno 
metric) assay. Detection of antigens using the monoclonal 
antibodies and their mimetics can be done utiliZing immu 
noassays which are run in either the forward, reverse, or 
simultaneous modes, including immunohistochemical assays 
on physiological samples. Those of skill in the art will know, 
or can readily discern, other immunoassay formats without 
undue experimentation. 
The compounds that bind CD123 and mimetics can be 
bound to many different carriers and used to detect the pres 
ence of CD123 bearing leukemia cells, including progenitor 
cells. Examples of well-known carriers include glass, poly 
styrene, polypropylene, polyethylene, dextran, nylon, amy 
lase, natural and modi?ed cellulose, polyacrylamide, agarose 
and magnetite. The nature of the carrier can be either soluble 
or insoluble for purposes of the invention. Those skilled in the 
art will know of other suitable carriers for binding various 
compounds, or will be able to ascertain such, using routine 
experimentation. 
For purposes of the invention, CD123 may be detected by 
the compounds and their mimetics when present in biological 
?uids and tissues. Any sample containing a detectable amount 
of CD123 ectopeptide can be used. A sample can be a liquid 
such as urine, saliva, cerebrospinal ?uid, blood, serum or the 
like; a solid or semi-solid such as tissues, feces, or the like; or, 
alternatively, a solid tissue such as those commonly used in 
histological diagnosis. 
In Vivo Detection of CD123 
In using the CD123 binding compounds and mimetics for 
the in vivo detection of CD123, the detectably labeled com 
pound or its mimetic is given in a dose which is diagnostically 
effective. The term “diagnostically effective” means that the 
amount of detectably labeled compound, such as monoclonal 
antibody or mimetic is administered in suf?cient quantity to 
enable detection of the leukemia cells for which the com 
pounds or mimetics are speci?c. 
The concentration of detectably labeled compound or 
mimetic which is administered should be suf?cient such that 
the binding to CD123 or CD123-bearing leukemia cells, is 
detectable compared to the background. Further, it is desir 
able that the detectably labeled compound or mimetic be 
rapidly cleared from the circulatory system in order to give 
the best target-to-background signal ratio. 
As a rule, the dosage of detectably labeled compound or 
mimetic for in vivo diagnosis will vary depending on such 
factors as age, sex, and extent of disease of the individual. The 
dosage of the compound can vary from about 0.01 mg/kg to 
about 500 mg/kg, preferably about 0.1 mg/kg to about 200 
mg/kg, most preferably about 0.1 mg/kg to about 10 mg/kg. 
Such dosages may vary, for example, depending on whether 
multiple injections are given, on the tissue being assayed, and 
other factors known to those of skill in the art. 
For in vivo diagnostic imaging, the type of detection instru 
ment available is a major factor in selecting an appropriate 
radioisotope. The radioisotope chosen must have a type of 
decay which is detectable for the given type of instrument. 
Still another important factor in selecting a radioisotope for in 
vivo diagnosis is that the half-life of the radioisotope be long 
enough such that it is still detectable at the time of maximum 
uptake by the target, but short enough such that deleterious 
radiation with respect to the host is acceptable. Ideally, a 
radioisotope used for in vivo imaging will lack a particle 
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emission but produce a large number of photons in the 140 
250 keV range, which may be readily detected by conven 
tional gamma cameras. 
For in vivo diagnosis, radioisotopes may be bound to the 
compound either directly or indirectly by using an interme 
diate functional group. Intermediate functional groups which 
often are used to bind radioisotopes which exist as metallic 
ions are the bifunctional chelating agents such as diethylen 
etriaminepentacetic acid (DTPA) and ethylenediaminetetra 
acetic acid (EDTA) and similar molecules. Typical examples 
of metallic ions which can be bound to the monoclonal anti 
bodies and mimetics of the invention are 111In, 97Ru, 67Ga, 
68Ga, 72As, 89Zr, 99"'Tc, 123I and 201T1. 
In the diagnosis method of the invention, the compounds 
and mimetics can also be labeled with a paramagnetic isotope 
for purposes of in vivo diagnosis, as in magnetic resonance 
imaging (MRI) or electron spin resonance (ESR). In general, 
any conventional method for visualizing diagnostic imaging 
can be utilized. Usually gamma and positron emitting radio 
isotopes are used for camera imaging and paramagnetic iso 
topes for MRI. Elements which are particularly useful in such 
techniques include 157Gd, 55Mn, 162Dy, 52Cr and 56Fe. 
In the cell monitoring method of the invention, the com 
pounds and mimetics can be used in vitro and in vivo to 
monitor the course of leukemia disease therapy. Thus, for 
example, by measuring the increase or decrease in the bio 
logical molecules associated with such a diseases or changes 
in the concentration of CD123 ectopeptide or CD123 bearing 
leukemia cells present in the body or in various body ?uids, it 
would be possible to determine whether a particular thera 
peutic regimen aimed at ameliorating the above leukemia 
disease is effective. 
Prophylaxis and Therapy of Leukemia 
The CD123 speci?c compounds can also be used therapeu 
tically for treatment of leukemia in both humans and other 
animals. The term, “therapeutically” or “therapy” as used 
herein in conjunction with the method of the invention is 
directed to using CD123 binding compounds, such as anti 
CD123 monoclonal antibodies and their mimetics, which 
denotes both prophylactic as well as therapeutic administra 
tion and both passive immunization with substantially puri 
?ed polypeptide products, and mimetics, as well as gene 
therapy by transfer of polynucleotide sequences encoding the 
product or part thereof. Thus, the compounds and mimetics 
can be administered to high-risk subjects in order to lessen the 
likelihood and/or severity of leukemia relapse, or adminis 
tered to subjects already evidencing active leukemia disease. 
For certain applications, it is envisioned that pharmaco 
logic agents will serve as useful agents for attachment to the 
compounds, particularly cytotoxic or otherwise anticellular 
agents having the ability to kill or suppress the growth or cell 
division of leukemia cells. In general, the invention contem 
plates the use of any pharmacologic agent that can be conju 
gated to a CD123 binding compound and delivered in active 
form to the targeted cell. Exemplary anticellular agents 
include chemotherapeutic agents, radioisotopes as well as 
cytotoxins. In the case of chemotherapeutic agents, the inven 
tors propose that agents such as a hormone such as a steroid; 
an antimetabolite such as cytosine arabinoside, ?uorouracil, 
methotrexate or aminopterin; an anthracycline; mitomycin C; 
a vinca alkaloid; demecolcine; etoposide; mithramycin; cali 
cheamicin, CC-1065 and derivatives thereof, or an alkylating 
agent such as chlorambucil or melphalan, will be particularly 
preferred. Other embodiments may include agents such as a 
coagulant, a cytokine, growth factor, bacterial endotoxin or 
the lipid A moiety of bacterial endotoxin. In any event, it is 
proposed that agents such as these may be successfully con 
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jugated to antibodies in a manner that will allow their target 
ing, internalization, release or presentation to blood compo 
nents at the site of the targeted leukemia cells as required 
using known conjugation technology. 
In certain preferred embodiments, cytotoxic agents for 
therapeutic application will include generally a plant-, fun 
gus- or bacteria-derived toxin, such as an A chain toxins, a 
ribosome inactivating protein, (x-sarcin, aspergillin, restiric 
tocin, a ribonuclease, diphtheria toxin or pseudomonas exo 
toxin, to mention just a few examples. The use of toxin 
antibody constructs is well known in the art of immunotoxins, 
as is their attachment to antibodies. Of these, a particularly 
preferred toxin for attachment to antibodies will be a degly 
cosylated ricin A chain. Deglycosylated ricin A chain is pre 
ferred because of its extreme potency, longer half-life, and 
because it is economically feasible to manufacture a clinical 
grade and scale. 
In other preferred embodiments, the cytotoxic agent may 
be a radioisotope. Preferred radioisotopes include (x-emitters 
such as, for example, 211Astatine, 212Bismuth and 213Bis 
muth, as well as [3-emitters such as, for example, 13lIodine, 
90Yttrium, 177Lutetium, 15 3 Samarium and 109Palladium. 
As used herein, a “therapeutically effective amount” of a 
compound is a dosage large enough to produce the desired 
effect in which the symptoms of leukemia or the likelihood of 
onset of leukemia is decreased. A therapeutically effective 
amount is not, however, a dosage so large as to cause adverse 
side effects, such as hyperviscosity syndromes, pulmonary 
edema, congestive heart failure, and the like. Generally, a 
therapeutically effective amount may vary with the subject’ s 
age, condition, and sex, as well as the extent of the disease in 
the subject and can be determined by one of skill in the art. 
The dosage may be adjusted by the individual physician or 
veterinarian in the event of any complication. A therapeuti 
cally effective amount may vary from about 0.01 mg/kg to 
about 500 mg/kg, preferably from about 0.1 mg/kg to about 
200 mg/kg, most preferably from about 0.2 mg/kg to about 20 
mg/kg, in one or more dose administrations daily, for one or 
several days. 
In the method of the invention, the compounds and their 
mimetics can be administered by injection or by gradual 
infusion over time. The administration of the compounds and 
their mimetics may be, for example, intravenous, intraperito 
neal, intramuscular, intracavity, subcutaneous, or transder 
mal. 
Preparations for parenteral administration include sterile 
aqueous or non-aqueous solutions. suspensions, and emul 
sions. Examples of non-aqueous solvents are propylene gly 
col, polyethylene glycol, vegetable oils such as olive oil, and 
injectable organic esters such as ethyl oleate. Aqueous carri 
ers include water, alcoholic/aqueous solutions, emulsions or 
suspensions, including saline and buffered media. Parenteral 
vehicles include sodium chloride solution, Ringer’ s dextrose, 
dextrose and sodium chloride, lactated Ringer’ s or ?xed oils. 
Intravenous vehicles include ?uid and nutrient replenishers, 
electrolyte replenishers (such as those based on Ringer’s 
dextrose), and the like. Preservatives and other additives may 
also be present such as, for example, antimicrobials, anti 
oxidants, chelating agents, and inert gases and the like. 
Depending on the speci?c clinical status of the disease, 
administration can be made via any accepted systemic deliv 
ery system, for example, via oral route or parenteral route 
such as intravenous, intramuscular, subcutaneous or percuta 
neous route, or vaginal, ocular or nasal route, in solid, semi 
solid or liquid dosage forms, such as for example, tablets, 
suppositories, pills, capsules, powders, solutions, suspen 
sions, cream, gel, implant, patch, pessary, aerosols, col 
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lyrium, emulsions or the like, preferably in unit dosage forms 
suitable for easy administration of ?xed dosages. The phar 
maceutical compositions will include a conventional carrier 
or vehicle and a CD123 binding compound and, in addition, 
may include other medicinal agents, pharmaceutical agents, 
carriers, adjuvants, and so on. 
If desired, the pharmaceutical composition to be adminis 
tered may also contain minor amounts of non-toxic auxiliary 
substances such as wetting or emulsifying agents, pH buffer 
ing agents and the like, such as for example, sodium acetate, 
sorbitan monolaurate, triethanolamine oleate, and so on. 
The compounds of this invention are generally adminis 
tered as a pharmaceutical composition which comprises a 
pharmaceutical vehicle in combination with a CD 1 23 binding 
compound. The amount of the drug in a formulation can vary 
within the full range employed by those skilled in the art, e.g., 
from about 0.01 weight percent (wt %) to about 99.99 wt % of 
the drug based on the total formulation and about 0.01 wt % 
to 99.99 wt % excipient. 
The preferred mode of administration, for the conditions 
mentioned above, is oral administration using a convenient 
daily dosage regimen which can be adjusted according to the 
degree of the complaint. For said oral administration, a phar 
maceutically acceptable, non-toxic composition is formed by 
the incorporation of the selected CD123 binding compound 
in any of the currently used excipients, such as, for example, 
pharmaceutical grades of mannitol, lactose, starch, magne 
sium stearate, sodium saccharine, talc, cellulose, glucose, 
gelatin, sucrose, magnesium carbonate, and the like. Such 
compositions take the form of solutions, suspensions, tablets, 
pills, capsules, powders, sustained release formulations and 
the like. Such compositions may contain between about 0.01 
wt % and 99.99 wt % of the active compound according to this 
invention. 
Preferably the compositions will have the form of a sugar 
coated pill or tablet and thus they will contain, along with the 
active ingredient, a diluent such as lactose, sucrose, dicalcium 
phosphate, and the like; a disintegrant such as starch or 
derivatives thereof; a lubricant such as magnesium stearate 
and the like; and a binder such as starch, polyvinylpyrroli 
done, acacia gum, gelatin, cellulose and derivatives thereof, 
and the like. 
It is understood that by “pharmaceutical composition”, it is 
meant that the CD123 binding compound is formulated into a 
substance that is to be administered purposefully diagnosing 
or treating leukemia in the individual. And, by “pharmaceu 
tical composition”, it excludes those compositions that are 
used to administer to individuals as test compounds for a 
purpose other than as a diagnostic or treatment agent for 
leukemia. 
The invention is described in further detail hereinbelow. 
Several recent studies have suggested the presence and 
importance of stem cells in both the genesis and perpetuation 
ofAML. Phenotypically, cells described as CD34+/CD38— or 
CD34+/HLA-DR— appear to play a central role in the devel 
opment of leukemic populations (Bonnet D, et al., Human 
acute myeloid leukemia is organized as a hierarchy that origi 
nates from a primitive hematopoietic cell. Nat. Med. 1997, 3: 
730-737; Blair A, et al., Most acute myeloid leukemia pro 
genitor cells with long-term proliferative ability in vitro and 
in vivo have the phenotype CD34(+)/CD71(—)/HLA-DR—. 
Blood 1998, 92: 4325-35). Furthermore, there is evidence 
suggesting that such cells may be relatively resistant to che 
motherapeutic drugs, and consequently contribute to the phe 
nomenon of relapse (Terpstra W, et al., Fluorouracil selec 
tively spares acute myeloid leukemia cells with long-term 
growth abilities in immunode?cient mice and in culture. 
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Blood 1996, 88: 1944-50). Thus, a better understanding of 
LSC biology and the characterization of unique LSC antigens 
are essential to the development of better treatments forAML. 
While the various AML subtypes display considerable 
diversity with respect to developmental characteristics, phe 
notype, cytokine responsiveness, etc., there appears to be a 
marked degree of functional conservation at the level of more 
primitive leukemic cells. This feature has been demonstrated 
by the work of Bonnet et. al., in which a CD34+/CD38— 
subpopulation was shown to be suf?cient to establish leuke 
mia in NOD/SCID mice (Bonnet D, et al., Human acute 
myeloid leukemia is organized as a hierarchy that originates 
from a primitive hematopoietic cell. Nat. Med. 1997, 3: 730 
737). Similar studies by others have corroborated the exist 
ence of leukemic stem cells for both AML and CML and 
con?rmed their relatively homogeneous phenotype and func 
tional capacity (Blair A, Hogge et al., Most acute myeloid 
leukemia progenitor cells with long-term proliferative ability 
in vitro and in vivo have the phenotype CD34(+)/CD71(—)/ 
HLA-DR—. Blood 1998, 92: 4325-35; Holyoake T, et al., 
Isolation of a highly quiescent subpopulation of primitive 
leukemic cells in chronic myeloid leukemia. Blood 1999, 94: 
2056-64). However, to date, no study has identi?ed an anti 
genic feature of myeloid LSC’s that may allow their identi 
?cation or preferential targeting for ablative therapy. In this 
report, we have identi?ed an additional commonality among 
CD34+/CD38— AML stem cells, expression of CD123, 
which facilitates their discrimination from normal hemato 
poietic stem cells. While the CD123 antigen was readily 
detected at high levels on AML cells, the IL-3 receptor [3 
chain, CD131, was not detected. 
Our experiments indicate that the transcription factor 
IRF-l (Interferon regulatory factor-1) is over-expressed (in 6 
of 6 primary AML specimens examined). Previous studies by 
Korpelainen et. al. have shown that treatment of endothelial 
cells with IFN-y results in up-regulation of CD123 (Korpel 
ainen E I, et al., Interferon-gamma upregulates interleukin-3 
(IL-3) receptor expression in human endothelial cells and 
synergizes with IL-3 in stimulating major histocompatibility 
complex class II expression and cytokine production. Blood 
1995, 86: 176-82). Similarly, our own studies have shown that 
treatment of primary AML cells with IFN-y increases expres 
sion of CD123 (data not shown). Thus, aberrant expression of 
interferon regulatory molecules might play a role in control 
ling CD123 expression in AML cells. 
Expression of the CD123 antigen formally demonstrates 
that LSC’s are biologically distinct from their normal stem 
cell counterparts. Because CD123 is not readily found on 
normal hematopoietic stem cells, it provides a unique marker 
that can be used to identify malignant tissue. This feature may 
be useful for research purposes, as well as in minimal residual 
disease (MRD) studies. Further, the CD123 epitope repre 
sents a target to which therapeutic strategies may be directed. 
Previous clinical trials have used monoclonal antibodies 
against both the CD33 and CD45 antigens as a means to 
deliver radioisotopes to AML cells in vivo (Appelbaum F R., 
Antibody-targeted therapy for myeloid leukemia. Semin 
Hematol 1999, 36: 2-8.). In addition, several other recent 
studies have shown exciting results using monoclonal anti 
bodies speci?c to antigens on malignant cells such as CD20, 
CD52, and Her-2 (Maloney D G., Advances in immuno 
therapy of hematologic malignancies. Curr Opin Hematol 
1998; 5: 237-43; Sikic B I., New approaches in cancer treat 
ment. Ann Oncol 1999, 10 Suppl 6: 149-53). Antibodies to 
CD123 may be useful in a similar paradigm and will be 
capable of delivering a cytotoxic hit that speci?cally targets 
the leukemic stem cell population. 
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We have shown that CD123 represents a unique antigenic 
marker for the identi?cation of primitive leukemic cells from 
a broad range of human specimens across a broad range of 
leukemic diseases. Our studies show that CD123 is generally 
expressed at high levels and may be indicative of previously 
uncharacterized aspects of leukemia biology. 
The present invention will be further illustrated in the fol 
lowing, non-limiting Examples. The Examples are illustra 
tive only and do not limit the claimed invention regarding the 
materials, conditions, process parameters and the like recited 
herein. 
EXAMPLES 
Example 1 
Materials and Methods: Cell Processing 
Primary AML cells were obtained from the peripheral 
blood or bone marrow of patients. Normal bone marrow was 
obtained as waste material following pathological analysis, 
surgical marrow harvest, or from the National Disease 
Research Interchange (NDRI). Marrow cells were depleted of 
erythrocytes by suspending in 150 mM NH4Cl+10 mM 
NaHCO3 for 5 minutes, followed by two washes with phos 
phate buffered saline (PBS). Blood cells were subjected to 
Ficoll-Paque (Pharmacia) density gradient separation to iso 
late the mononuclear white blood cell compartment. Result 
ing leukocytes from marrow or blood were then used for 
immunoaf?nity selection, and/ or ?ow cytometric analysis or 
sorting. For CD34+ cell selection, the Miltenyi immunoa?in 
ity device (varioMACS) was used according to the manufac 
turer’s instructions. In some cases, leukocytes were cryopre 
served at a concentration of 5><107 cells/ml in freezing 
medium consisting of Iscoves modi?ed Dulbecco medium 
(IMDM), 40% fetal bovine serum (FBS) and 10% dimethyl 
sulfoxide (DMSO). 
Example 2 
Flow Cytometry 
Cytokine receptors were detected by labeling with the fol 
lowing monoclonal antibodies: CD114-biotin, CD1 16-FITC, 
CD123-PE, CD131-biotin (all from Pharmingen), CD117 
PE (Coulter), and CD135-PE (Caltag). Biotinylated antibod 
ies were visualized by subsequent labeling with streptavidin 
PE (SA-PE, Becton Dickinson). Primitive AML 
subpopulations were identi?ed using CD34-FITC or CD34 
PE in combination with CD38-APC (Becton Dickinson). Pri 
mary AML cells were identi?ed in NOD/SCID mice using 
CD45-PE (Pharmingen) speci?c to human cells. To analyze 
cells transplanted into NOD/SCID mice, bone marrow was 
harvested at 6-8 weeks post-transplantation. Cells were 
blocked with the anti-Fc receptor antibody 2.4G2 and 25% 
human serum, followed by double-labeling with human-spe 
ci?c CD34-FITC and CD45-PE antibodies. Control samples 
consisted of marrow cells from non-transplanted mice. In 
some cases, cells were also labeled with CD123-PE to ensure 
sustained expression of the CD123 antigen. For each speci 
men 50,000-100,000 events were analyzed. Using this 
approach, human cells could reliably be detected to a fre 
quency as low as 0.1%. Any analysis falling below 0.1% 
positive cells was considered negative. 
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Example 3 
Immunoblots 
Cell samples were lysed at a concentration of 2><107 cells/ 
ml in PBS containing: 1% NP-40, 0.5% deoxycholate, 0.1% 
sodium dodecyl sulfate (SDS), 1 mM sodium vanadate 
(Na3VO4), 30 pl aprotinin (Sigma), 1 mM phenylmethylsul 
fonyl ?uoride (Sigma), 1 11ng pepstatin, and 1 11ng leu 
peptin (Oncogene Research); incubated on ice for 30 minutes, 
and centrifuged at 15,000><g for 10 minutes to remove debris. 
The resulting protein lysate was then aliquoted and stored at 
—80° C. For immunoblot analysis, protein lysates were 
thawed and mixed with sample buffer and reducing agent 
(Novex, San Diego, Calif., per manufacturer’s instructions), 
and heated at 70° C. for 10 minutes. Samples were then 
immediately analyzed by denaturing PAGE (Novex, 4-12% 
Bis-Tris or 7% Tris-Acetate gels) using the equivalent of 
4><105 cells per lane. Following electrophoresis, samples 
were electro-transferred onto Immobilon-P membrane (Mil 
lipore) and probed with the indicated antibodies. To detect 
CD123 (IL-3R alpha chain), antibodies S-12 (Santa Cruz 
Biotech) or 9F5 (Pharmingen) were used. For the analysis of 
Mek and Akt, protein-speci?c and phosphoprotein-speci?c 
rabbit polyclonal antibodies from New England Biolabs were 
used. Anti-Stat5 polyclonal (Transduction Labs) and anti 
phospho-Stat5 (New England Biolabs) were used to analyze 
the phosphorylation status of Stat5. All primary antibodies 
were detected using alkaline phosphatase-conjugated sec 
ondary antibodies (Santa Cruz Biotechnology) and the ECF 
reagent (Pharmacia Biotech) per manufacturer’ s instructions. 
Blots were visualized using a Molecular Dynamics STORM 
860 system and ImagequantTM Software. 
Example 4 
NOD/SCID Mouse Assays 
NOD/SCID mice (Jackson Laboratories, Bar Harbor, Me.) 
were exposed to 225 rads of y-irradiation from a 137Cs source. 
Cells to be assayed were resuspended in 0.25 mls HBSS 
(Hanks balanced salt solution, Gibco) with 2% FBS and 
injected IV into the tail vein. For the analysis of some sorted 
populations, 1><106 irradiated (2500 Rads) mouse bone mar 
row cells were co-inj ected as carrier. After 6-8 weeks, animals 
were sacri?ced and bone marrow was analyzed for the pres 
ence of human cells using ?ow cytometry (see above). 
Example 5 
Results 
Analysis of cytokine receptors demonstrates strong 
expression of CD123 on primitive leukemic but not normal 
cells. Multiparameter ?ow cytometry was used to analyze the 
expression of cytokine receptors previously implicated in the 
growth of malignant hematopoietic cells. While several 
receptors displayed interesting patterns of antibody labeling, 
the most striking feature observed was a remarkably high and 
well-conserved level of CD123 (IL-3R alpha chain) expres 
sion amongst primary AML specimens. FIG. 1 shows repre 
sentative examples of CD123 labeling in normal and leuke 
mic tissue. In FIG. 1A total normal marrow, as well as more 
primitive subsets, are shown with respect to CD123 expres 
sion. Total marrow generally has about 7% positive cells for 
CD123, but only about 1% of the population expresses the 
antigen at high levels (see inset FIG. 1A). The CD34+ popu 
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lation of normal marrow also has readily evident CD123 
expression (12% in FIG. 1A, right histogram), as would be 
expected for a population known to contain hematopoietic 
progenitors. The labeling pro?le shown is in good agreement 
with previous studies by Sato et. al. that have also examined 
IL-3RO. levels on human CD34+ cells (Sato N, et al., Expres 
sion and factor-dependent modulation of the interleukin-3 
receptor subunits on human hematopoietic cells. Blood 1993, 
82: 752-61.). However, the more primitive CD34+/CD38— 
compartment shows no signi?cant expression of CD123 
(<1%). In contrast, primary AML cells (FIG. 1B) displayed 
high levels of CD123. In both the overall CD34+ population, 
as well as the more primitive CD34+/CD38— compartment, 
greater than 99% of the cells were positive for CD123. FIG. 2 
shows ?ve additional examples of CD123 labeling on 
CD34+/CD38— AML cells, further demonstrating the strong 
expression of this antigen on leukemic populations. Table 1 
summarizes the experiments performed to date on the AML 
cell type, and shows CD123 levels for primitive cells of AML 
subtypes M1, M2, and M4. Of the 18 primary AML speci 
mens examined, CD123 was strongly expressed on the primi 
tive leukemia cells in all but two instances. The two samples 
which had lower CD123 levels (samples AML-11 and AML 
14, Table I) both displayed a uniform shift in CD123 expres 
sion, but had an overall labeling intensity that was dimmer 
than most samples assayed. In many cases (9 of 18), CD123 
negative cells were virtually undetectable (0% or less than 
1%). Conversely, expression of CD123 was not detected on 3 
of 5 normal samples of CD34+/CD38— cells and was barely 
detectable in two additional specimens (<1%). These ?ow 
cytometric analyses were con?rmed using two different anti 
CD123 monoclonal antibodies to insure that the results were 
not an artifact caused by the use of a particular antibody. 
The high level of CD123 expression found on all AML 
subtypes examined implies that IL-3RO. might play a central 
role in creating or maintaining the leukemic state. To form the 
high af?nity receptor for IL-3, both the 0t and [3 chains 
(CD123 and CD131 respectively) are necessary. Thus, 
expression of CD131 was also examined by ?ow cytometry 
on the AML specimens. Interestingly, while some expression 
was seen in bulk AML populations, in 15 of 15 specimens 
CD131 was never detected in the CD34+ compartment (data 
not shown). 
Further data demonstrating CD123 expression in primary 
ALL and primary CML cells, as well as non-Hodgkin’s lym 
phoma, are discussed in Examples 8 and 10. 
Example 6 
In Vivo Engraftment Properties of Human CD123+ 
Leukemia Cells in NOD/SCID Mice 
Given the strong CD123 expression observed on the vast 
majority of cells that phenotypically encompass the LSC 
population, it appeared likely that CD123 would be useful as 
a marker of LSC’s. Therefore, to establish the functional 
capacity of CD123+ cells, transplantation studies using the 
NOD/SCID mouse model system were performed. Three pri 
mary AML specimens (AML-2, 5, and 15 from Table 1) were 
assayed by ?ow cytometrically sorting CD34+/CD123+ cells 
and transplanting them into irradiated NOD/SCID mice. In 
addition, the remaining cells in the population (CD34—/ 
CD123 +/—) were also sorted and transplanted in parallel. The 
data in FIG. 3 are a representative example of one specimen 
that showed strong engraftment of leukemic cells at six weeks 
post-engraftment. Panel A shows total bone marrow cells 
labeled with antibodies speci?c to human CD34 and CD45. 
The ?ow cytometric pro?le clearly indicates that a large 
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population of human cells (CD45+) is present in the marrow. 
In addition, the population is divided between CD34+ and 
CD34— subsets, similar to the proportions of CD34 labeling 
seen in the original leukemic specimen. Panel B shows the 
same marrow sample gated only on the CD45+ cells. The data 
indicate that all of the cells that have proliferated in vivo are 
CD123 positive. Table 2 summarizes the data for the three 
specimens tested. In all cases, the CD123+ cells were capable 
of engrafting the NOD/SCID animals. Moreover, in all but 
one instance, the CD123— populations did not contribute to in 
vivo repopulation. Thus, as de?ned by the NOD/SCID model, 
we conclude that CD123 is expressed on the LSC. 
Finally, as an independent means of con?rming the leuke 
mic origin of CD123 positive cells, ?ow cytometry was used 
to sort CD34+/CD123+ cells from two leukemic specimens. 
These samples were cultured for four days, synchronized and 
then harvested for cytogenetic analysis. Examination of 
spreads from each specimen showed that 20 out of 20 
metaphases was positive for the leukemia-speci?c transloca 
tion. 
Example 7 
Biological Role of CD123 Expression in Leukemia 
Cells 
To further corroborate the data obtained by ?ow cytometry, 
immunoblot studies were performed to analyze IL-3R signal 
transduction components. For these studies, each AML 
sample was derived from a peripheral blood specimen and 
was sorted to isolate the CD34+ population, thus insuring a 
virtually pure leukemic sample. First, expression of both the 
IL-3R0t and [3 chains were examined. With respect to CD123, 
the data shown in FIG. 4 (top panel) clearly demonstrate 
expression in all leukemic samples assayed. The CD34+ cells 
derived from normal marrow (lane 2, CD34+) also show a 
weak signal. This is consistent with the data in FIG. 1A, 
which show that normal CD34+ cells often contain a small 
subset of CD123+ cells. However, CD123 expression was not 
detected by ?ow cytometry in the more primitive CD34+/ 
CD38— subset of normal cells (FIG. 1A and Table 1). Due to 
their low frequency, it was not possible to obtain suf?cient 
CD34+/CD38— cells of either normal or AML origin for 
direct analysis by immunoblot. Nonetheless, detection of a 
clear signal in the overall CD34+ population corroborates the 
strong signal seen by ?ow cytometry for AML cells. Another 
point to note is that the molecular weight of the CD123 band 
appears to vary slightly between AML samples. We have 
performed RT-PCR ?ngerprint analyses of the same speci 
mens and seen no obvious aberrancies (data not shown). 
Thus, it appears that varying degrees of post-translational 
modi?cation are the most likely explanation for this observa 
tion. Consistent with the results obtained by ?ow cytometry, 
expression of CD131 was not detected (FIG. 4, bottom 
panel). 
To begin exploring a potential functional role for CD123, 
we examined the response of primary AML cells to IL-3. 
Typically, stimulation of hematopoietic cells with IL-3 leads 
to several well-characterized intracellular signal transduction 
events (Hara T, et al., Function and signal transduction medi 
ated by the interleukin 3 receptor system in hematopoiesis. 
Stem Cells 1996, 14: 605-18). Prevalent among these events 
are phosphorylation of Mek-1, Akt, and Stat-5 (Songyang Z, 
et al., Interleukin 3-dependent survival by the Akt protein 
kinase. Proc Natl Acad Sci USA 1997, 94: 11345-50; Yag 
isawa M, et al., Signal transduction pathways in normal 
human monocytes stimulated by cytokines and mediators: 
comparative study with normal human neutrophils or trans 
formed cells and the putative roles in functionality and cell 
biology. Exp Hematol 1999, 27: 1063-76; Sutor S L, et al., A 
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phosphatidylinositol 3 -kinase-dependent pathway that differ 
entially regulates c-Raf and A-Raf. J Biol Chem 1999, 274: 
7002-10; de Groot R P, et al., Regulation of proliferation, 
differentiation and survival by the lL-3/lL-5/GM-CSF recep 
tor family. Cell Signal 1998, 10: 619-28). Consequently, 
immunoblot studies were performed on these proteins to 
assess the degree of phosphorylation, both in the presence or 
the absence of lL-3 stimulation. The data, shown in FIG. 5, 
show no detectable phosphorylation of Akt and Stat5 in the 
absence of lL-3, and only a moderate level of phosphorylation 
for Mek-l. Furthermore, in response to lL-3 stimulation, no 
appreciable increase in phosphorylation is seen for any of the 
proteins assayed. These results suggest that CD123 present 
on the surface of primary AML cells does not contribute 
signi?cantly to signal transduction via conventional lL-3 
mediated pathways. 
Example 8 
CD123 Expression in Primary ALL and Primary 
CML Cells 
Similar experimental protocol as described in Examples 1 
through 4 were followed, and the expression of CD123 was 
assayed in primary ALL and primary CML cells by ?ow 
cytometry. The results were consistent with the results 
obtained with expression of CD123 in primary AML in 
Example 5. FIGS. 6A, 6B, and 6C show reproducibly that the 
primary ALL cells express CD123. Moreover, FIGS. 7A, 7B, 
and 7C show reproducibly that the primary CML cells also 
express CD123. 
Example 9 
CD123 Targeted Complement-Kill Assay 
By using a complement-kill assay, “Current protocols in 
Immunology” Edited by John Coligan, Ada Kruisbeek, David 
Margulies, Ethan Shevach, and Warren Strober, John Wiley 
and Sons publishing, 1992, which is incorporated by refer 
ence herein in its entirety, this experiment demonstrates that 
CD123+ cells are preferentially targeted. In this experiment, 
we compared a typical AML specimen (i.e. CD123+) to a 
normal bone marrow sample. For each specimen there is an 
untreated control, a sample treated with complement alone, 
and a sample treated with anti-CD123+ complement. As 
shown in Table 3, there is a substantial complement-killing 
effect on the AML specimen, but no effect on the normal 
marrow. This is true for both the overall sample, as well as the 
more primitive CD34+ cells. Accordingly, this experiment 
demonstrates that there is a difference between the effect on 
normal and leukemic cells with respect to the speci?city for 
CD123. 
Example 10 
CD123 Expression in Lymphoma Cells 
lmmunohistochemical analysis of tissue sections showed 
that “diffuse large B cell lymphoma” is strongly positive for 
expression of CD123. This is the most common form of 
non-Hodgkin’s lymphoma. Thus, in a B-cell derived cancer, 
expression of CD123 is consistent with the observation that 
CD123 was also observed onALL cells (i.e. another type of B 
cell cancer). This observation directly identi?es B cell lym 
phomas as a target for therapies and diagnostics using 
CD123. 
All of the cited references are incorporated by reference 
herein in their entirety. 
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Those skilled in the art will recognize, or be able to ascer 
tain using no more than routine experimentation, many 
equivalents to the speci?c embodiments of the invention spe 
ci?cally described herein. Such equivalents are intended to be 
encompassed in the scope of the following claims. 
TABLE 1 
Expression of CD123 in Primitive Leukemic and Normal Cells. 
% CD123+ cells in 
Specimen FAB CD34+/ CD3 8— population 
AML 
AML-1 MDS/AML 100% 
AML-2 M1 100% 
AML-3 M1 95.2% 
AML-4 M4 98.1% 
AML-5 M2 99.7% 
AML-6 M4 99.5% 
AML-7 nd 100% 
AML-8 M4 99.7% 
AML-9 M4 99.8% 
AML- 10 M2 100% 
AML-11 MDS/AML 70.2% 
AML- 12 nd 92.5% 
AML- 13 M1 97 .5 % 
AML- 14 M4 51.1% 
AML- 15 M4 98.1% 
AML-16 M1 95 .3 % 
AML- 17 M1 98.9% 
AML-18 M4 100% 
Normal Marrow 
BM—l na 0 
BM—2 na <1 % 
BM—3 na 0 
BM—4 na 0 
BM—5 na <1 % 
FAB = French, American, British classi?cation system 
MDS/AML = myelodysplastic syndrome progressing to AML 
na = not applicable 
TABLE 2 
Engra?ment ofCD123+ Populations in NOD/SCID Mice. 
Population Cells % CD45+ 
Exp. Specimen Assayed (N) Inj./mouse cells/recip. 
1 AML-2 CD34+/CD123+ (3) 4.9 x 10e6 42% 
18% 
67% 
CD34—/CD123+/— (3) 7.5 x 10e5 nd 
0.2% 
0.1% 
2 AML-5 CD34+/CD123+ (4) 2.5 x 10e6 15% 
6% 
1% 
12% 
CD34—/CD123+/— (3) 2.5 x 10e6 nd 
nd 
nd 
3 AML-15 CD34+/CD123+ (5) 2.1 x 10e6 2.1% 
0.2% 
0.8% 
1.1% 
0.9% 
CD34—/CD123+/— (3) 2.4 x 10e6 nd 
nd 
nd 
N = number ofmice assayed 
nd = not detectable 

